Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists

被引:628
作者
Bahn, Rebecca S. [1 ]
Burch, Henry B. [2 ]
Cooper, David S. [3 ]
Garber, Jeffrey R. [4 ]
Greenlee, M. Carol [5 ]
Klein, Irwin [6 ]
Laurberg, Peter [7 ]
McDougall, I. Ross [8 ,9 ]
Montori, Victor M. [1 ]
Rivkees, Scott A. [10 ]
Ross, Douglas S. [11 ]
Sosa, Julie Ann [12 ,13 ]
Stan, Marius N. [1 ]
机构
[1] Mayo Clin, Div Endocrinol Metab & Nutr, Rochester, MN 55905 USA
[2] Walter Reed Army Med Ctr, Div Endocrinol & Metab, Washington, DC 20307 USA
[3] Johns Hopkins Univ, Sch Med, Div Endocrinol, Baltimore, MD USA
[4] Harvard Vanguard Med Associates, Div Endocrine, Boston, MA USA
[5] Western Slope Endocrinol, Grand Junction, CO USA
[6] N Shore Univ Hosp, Thyroid Unit, Manhasset, NY USA
[7] Aarhus Univ Hosp, Dept Endocrinol, Aalborg, Denmark
[8] Stanford Univ, Sch Med, Dept Radiol, Div Nucl Med, Stanford, CA 94305 USA
[9] Stanford Univ, Dept Med, Sch Med, Div Endocrinol, Stanford, CA 94305 USA
[10] Yale Pediat Thyroid Ctr, Dept Pediat, New Haven, CT USA
[11] Massachusetts Gen Hosp, Boston, MA 02114 USA
[12] Yale Univ, Sch Med, Div Endocrine Surg, New Haven, CT USA
[13] Yale Univ, Sch Med, Div Surg Oncol, New Haven, CT USA
关键词
ANTINEUTROPHIL CYTOPLASMIC ANTIBODY; AMIODARONE-INDUCED THYROTOXICOSIS; PERCUTANEOUS ETHANOL INJECTION; HUMAN CHORIONIC-GONADOTROPIN; DRUG-INDUCED AGRANULOCYTOSIS; RADIOACTIVE IODINE THERAPY; QUALITY-OF-LIFE; ENDOGENOUS SUBCLINICAL HYPERTHYROIDISM; MULTINODULAR TOXIC GOITER; PARATHYROID-HORMONE ASSAY;
D O I
10.1089/thy.2010.0417
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Thyrotoxicosis has multiple etiologies, manifestations, and potential therapies. Appropriate treatment requires an accurate diagnosis and is influenced by coexisting medical conditions and patient preference. This article describes evidence-based clinical guidelines for the management of thyrotoxicosis that would be useful to generalist and subspeciality physicians and others providing care for patients with this condition. Methods: The development of these guidelines was commissioned by the American Thyroid Association in association with the American Association of Clinical Endocrinologists. The American Thyroid Association and American Association of Clinical Endocrinologists assembled a task force of expert clinicians who authored this report. The task force examined relevant literature using a systematic PubMed search supplemented with additional published materials. An evidence-based medicine approach that incorporated the knowledge and experience of the panel was used to develop the text and a series of specific recommendations. The strength of the recommendations and the quality of evidence supporting each was rated according to the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation Group. Results: Clinical topics addressed include the initial evaluation and management of thyrotoxicosis; management of Graves' hyperthyroidism using radioactive iodine, antithyroid drugs, or surgery; management of toxic multinodular goiter or toxic adenoma using radioactive iodine or surgery; Graves' disease in children, adolescents, or pregnant patients; subclinical hyperthyroidism; hyperthyroidism in patients with Graves' ophthalmopathy; and management of other miscellaneous causes of thyrotoxicosis. Conclusions: One hundred evidence-based recommendations were developed to aid in the care of patients with thyrotoxicosis and to share what the task force believes is current, rational, and optimal medical practice.
引用
收藏
页码:593 / 646
页数:54
相关论文
共 358 条
[1]   Re-operation for bleeding after thyroidectomy and parathyroidectomy [J].
Abbas, G ;
Dubner, S ;
Heller, KS .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2001, 23 (07) :544-546
[2]   A systematic review of drug therapy for Graves' hyperthyroidism [J].
Abraham, P ;
Avenell, A ;
Park, CM ;
Watson, WA ;
Bevan, JS .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 153 (04) :489-498
[3]  
Abraham P, 2005, COCHRANE DB SYST REV, V18
[4]   Graves' disease:: A long-term quality-of-life follow up of patients Randomized to treatment with antithyroid drugs, radioiodine, or surgery [J].
Abraham-Nordling, M ;
Törring, O ;
Hamberger, B ;
Lundell, G ;
Tallstedt, L ;
Calissendorff, J ;
Wallin, G .
THYROID, 2005, 15 (11) :1279-1286
[5]   Incidence of hyperthyroidism in Stockholm, Sweden, 2003-2005 [J].
Abraham-Nordling, Mirna ;
Torring, Ove ;
Lantz, Mikael ;
Hallengren, Bengt ;
Ohrling, Hans ;
Lundell, Goran ;
Calissendorff, Jan ;
Jorneskog, Gun ;
Wallin, Goran .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2008, 158 (06) :823-827
[6]  
AHMED K, 2010, ENDOCR PRACT, V9, P1
[7]   Thiamazole as an adjuvant to radioiodine for volume reduction of multinodular goiter [J].
Albino, Claudio ;
Graf, Hans ;
Sampaio, Ana P. ;
Vigario, Adriano ;
Paz Filho, Gilberto J. .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (12) :1781-1786
[8]   High dose 131I therapy for the treatment of hyperthyroidism caused by Graves' disease [J].
Alexander, EK ;
Larsen, PR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (03) :1073-1077
[9]   Age and gender predict the outcome of treatment for Graves' hyperthyroidism [J].
Allahabadia, A ;
Daykin, J ;
Holder, RL ;
Sheppard, MC ;
Gough, SCL ;
Franklyn, JA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (03) :1038-1042
[10]  
AlSuliman NN, 1997, EUR J SURG, V163, P13